Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-12-16

Clinical Trial Update: A Study of Pembrolizumab in People With Ultra-Rare Sarcomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for pembrolizumab in ultra-rare sarcomas, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: RECRUITING